Vnitr Lek 2009, 55(Suppl 1):125-144

Differential diagnosis of eosinophilia

Z. Adam*, M. Tomíška, M. Krejčí, L. Pour
Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc.

Elevated eosinophil count might be a sign of many different pathologies. Most frequently, this is a result of allergic conditions. Elevated eosinophil count associated with a parasitic infection is considered as physiological. Eosinophilia may be linked to certain organ and connective tissue disorders. The primary increase in eosinophil count may be caused by pathologic (benign or malignant) cloning of T-lymphocytes that, through their cytokines, stimulate proliferation and differentiation of eosinophilic lineage. Nonetheless, the primary malfunction could also be directly in the myeloid cell line. Some of the myeloid cell mutations associated with uncontrolled eosinophilic myeloproliferation have been described, others are awaiting identification. The aim of this paper is to describe all states that result in elevated peripheral blood eosinophil count and provide directions for differential diagnosis.

Keywords: eosinophilia; hypereosinophilic syndrome; eosinophilic leukaemia

Received: February 25, 2009; Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adam Z, Tomíška M, Krejčí M, Pour L. Differential diagnosis of eosinophilia. Vnitr Lek. 2009;55(Supplementum 1):125-144.
Download citation

References

  1. Adam Z, Elbl L, Bulíková A et al. Eozinolie, idiopatický hypereozinolní syndrom/chronická eozinofilní leukémie. Postgrad Med 2003; 5: 471-487.
  2. Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007; 27: 377-388. Go to original source... Go to PubMed...
  3. Bohm M, Richter JE. Treatment of eosinophilic esophagitis: overview, current limitations, and future direction. Am J Gastroenterol 2008; 103: 2635-2644. Go to original source... Go to PubMed...
  4. Capovilla M, Cayuela JM, Bilhou-Nabera C et al. Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy. Eur J Haematol 2008; 80: 81-86. Go to original source...
  5. Carnero-Alcázar M, Reguillo-Lacruz F, O'Connor F et al. Hypereosinophilic syndrome and myocardial fibrosis. Interact Cardiovasc Thorac Surg 2008; 7: 928-930. Go to original source... Go to PubMed...
  6. Cilloni D, Messa F, Martinelli G et al. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia 2007; 21: 1442-1450. Go to original source... Go to PubMed...
  7. Corradi D, Maestri R, Facchetti F. Postpartum Churg-Strauss syndrome with severe cardiac involvement: Description of a case and review of the literature. Clin Rheumatol 2009. V tisku. Go to original source...
  8. D'Angelo G, Hotz AM, Todeschin P. Acute lymphoblastic leukemia with hypereosinophilia and 9p21 deletion: case report and review of the literature. Lab Hematol 2008; 14: 7-9. Go to original source... Go to PubMed...
  9. do Prado AD, de Figueiredo CE, Marrone CD et al. Episcleris, arthrofasciitis and hypereosinophilia: primary hypereosinophilic syndrome or atypical Wegener's granulomatosis? Rheumatol Int 2007; 28: 89-90. Go to original source... Go to PubMed...
  10. Duval A, Bergoin E, Maynadié M et al. Images in haematology. Hypereosinophilia as a presenting feature of anaplastic large cell lymphoma. Br J Haematol 2008; 140: 363. Go to original source... Go to PubMed...
  11. Estrada-Reyes E, Hernnández-Román MP, Gamboa-Marrufo JD et al. Hypereosinophilia, hyper-IgE syndrome, and atopic dermatitis in a toddler with food hypersensitivity. J Investig Allergol Clin Immunol 2008; 18: 131-135.
  12. Garcia-Alvarez A, Sitges M, Garcia-Albeniz X et al. Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib. Int J Cardiol 2008. V tisku.
  13. González Delgado P, de la Sen Fernández ML, Soriano Gomis V et al. Cyclical hypereosinophilia with skin manifestations and a clonal T cell population. J Investig Allergol Clin Immunol 2008; 18: 401-403.
  14. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22: 1999-2010. Go to original source... Go to PubMed...
  15. Haghpanah V, Lashkari A, Tavangar SM et al. Hypereosinophilia as the presentation of metastatic medullary thyroid carcinoma: a remarkable event. Am J Med Sci 2000; 334: 131-132. Go to original source... Go to PubMed...
  16. Helbig G, Stella-Hołowiecka B, Majewski M et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008; 141: 200-204. Go to original source... Go to PubMed...
  17. Husár R, Václavík J, Lukl J. Newly diagnosed Churga-Strauss syndrome in a female patient with suspect acute coronary syndrome. Vnitř Lék 2008; 54: 1102-1105. Go to PubMed...
  18. Chrobák L, Voglová J. Idiopatický hypereozinofilní syndrom a chronická eozinolní leukemie. Vnitř Lék 2005; 51: 1385-1393. Go to PubMed...
  19. Iwata H, Tsuboi N, Ishii T et al. Hypereosinophilia associated with increased serum levels of carcinoembryonic antigen. Intern Med 2008; 47: 963-967. Go to original source... Go to PubMed...
  20. Kahn JE, Blétry O, Guillevin L. Hypereosinophilic syndromes. Best Pract Res Clin Rheumatol 2008; 22: 863-882. Go to original source... Go to PubMed...
  21. Kalac M, Quintás-Cardama A, Vrhovac R et al. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 2007; 110: 955-964. Go to original source... Go to PubMed...
  22. Lee JH, Park HK, Heo J et al. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci 2008; 23: 521-525. Go to original source... Go to PubMed...
  23. Macků M, Rybníček P, Tomanová Y et al. Eosinofilie - nesnadný hlavolam. Pediatr pro Prax 2005; 6: 35-37.
  24. Nakagome K, Dohi M, Okunishi K et al. IL-5-induced hypereosinophilia suppresses the antigen-induced immune response via a TGF-beta-dependent mechanism. J Immunol 2007; 179: 284-294. Go to original source... Go to PubMed...
  25. Nathan N, Guillemot N, Aubertin G et al. Chronic eosinophilic pneumonia in a 13-year-old child. Eur J Pediatr 2008; 167: 1203-1207. Go to original source... Go to PubMed...
  26. Oberholzer C, Nüesch R, Häusermann P. Urticaria and parasites: case report and general view over the most common pathogens of chronic urticaria. Praxis (Bern 1994) 2007; 96: 865-870. Go to original source...
  27. Quintás-Cardama A, Cortes J. Therapeutic options for patients with clonal and idiopathic hypereosinophia. Expert Opin Investig Drugs 2008; 17: 1039-1050. Go to original source... Go to PubMed...
  28. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27: 389-413. Go to original source... Go to PubMed...
  29. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007; 2: 37. Go to original source... Go to PubMed...
  30. Sade K, Mysels A, Levo Y et al. Eosinophilia: A study of 100 hospitalized patients. Eur J Intern Med 2007; 18: 196-201. Go to original source... Go to PubMed...
  31. Sheikh J, Weller PF. Advances in diagnosis and treatment of eosinophilia. Curr Opin Hematol 2009; 16: 3-8. Go to original source... Go to PubMed...
  32. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27: 333-355. Go to original source... Go to PubMed...
  33. Sun CY, Hu Y, Chu ZB et al. Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate. Int J Hematol 2009; 89: 66-70. Go to original source... Go to PubMed...
  34. Šteruská M, Demečková E, Benžová M et al. Hypereozinofilný syndróm - leukemia, lymfómy, myeloproliferatívny a myelodysplastický syndróm s eozinofíliou. Hemat Transfuz 1994; 4: 14-22.
  35. Vaida I, Roszkiewicz F, Gruson B et al. Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia. Pharmacology 2009; 83: 148-149. Go to original source... Go to PubMed...
  36. Zavřelová A, Žák P. BCR/ABL negativní myeloproliferativní onemocnění s eozinofilií. Lék Zprav 2006; 51: 197-198.
  37. Tefferi A. Eosinophilia: secondary, clonal and idiopatic. Brit J Hematol 2006; 133: 468-492. Go to original source... Go to PubMed...
  38. Brigden ML. A practical workup for eosinophilia. Postgraduate Med 1999; 105: 193-211. Go to original source... Go to PubMed...
  39. Vaillant L. Drug hypersensitivity syndrome: drug rash, with eosinophilia and systemic symptoms - DRESS. J Dermatol Treatment 1999; 10: 267-272. Go to original source...
  40. Cottin V. Churg-Strauss syndrome. J Allergy 1999; 54: 535-551. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.